Myriad Officers & Directors

	John T. Henderson, M.D. Chairman of the Board John T. Henderson, M.D. was elected as Chairman of the Board in April 2005. He previously served as a Director of the Company effective May 2004. Dr. Henderson was with Pfizer for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held Vice Presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for Europe, U.S. and International Pharmaceuticals group. Dr. Henderson earned his bachelor's and medical degree from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.).

	Walter Gilbert, Ph.D. Director Vice Chairman of the Board Managing Director, BioVentures Investors Walter Gilbert, Ph.D., Vice Chairman of the Board of Directors, joined the Company as a founding scientist in March 1992. Dr. Gilbert won the Nobel Prize in Chemistry in 1980 for his contributions to the development of DNA sequencing technology. He was a founder of Biogen, Inc. and its Chairman of the Board and Chief Executive Officer from 1981 to 1985, as well as the Carl M. Loeb University Professor at Harvard University. He is presently a Managing Director of BioVentures Investors.

	Peter D. Meldrum Director President and CEO Myriad Genetics, Inc. Peter D. Meldrum has been a Director of the Company since its inception in May 1991 and has been President and Chief Executive Officer of the Company since November 1991. Prior to joining the Company he was President and Chief Executive Officer of Founders Fund, Inc., a venture capital group specializing in the biotechnology industry. He received a D.Sc. (Honorary) from Westminster College in 2004, an M.B.A. degree from the University of Utah in 1974 and a B.S. degree in Chemical Engineering from the University of Utah in 1970.

	Gerald P. Belle Director Former President and CEO, North American Pharmaceuticals, Aventis, Inc. Mr. Belle was previously President and CEO, North American Pharmaceuticals, Aventis, Inc., until his retirement from the Company in 2004, after more than 35 years of service, the majority of which was in executive commercial and general management positions in Asia, Europe/Middle East/Africa and Canada. Following retirement from Aventis, he was appointed Executive Chairman of Merial, Ltd., a global leader in animal health and a joint venture between Merck and sanofi-aventis.
	Robert S. Attiyeh Director Former CFO and Senior Vice President of Amgen, Inc. Robert S. Attiyeh joined the Company in December 2003. Mr. Attiyeh served Amgen as its Chief Financial Officer and Senior Vice President, Finance and Corporate Development from 1994 to 1998. Prior to joining Amgen, he was a director of McKinsey and Company, a management-consulting firm, from 1967 to 1994. He served as a Director of the Federal Reserve Bank of San Francisco from 1987 through 1992, and Chairman of the Federal Reserve Bank's Audit Review Committee from 1988 through 1992. He received his MBA from Harvard University in 1961 and his bachelor's degree in electrical engineering from Cornell University.
	Dennis Langer, M.D., J.D. Director Managing Partner, Phoenix IP Ventures Dennis Langer, M.D., J.D. is a Director of the Company as of May 2004. He was previously Senior Vice President in Research and Development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer has earned a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.

	Mark H. Skolnick, Ph.D. Director Chief Scientific Officer Myriad Genetics, Inc. Mark H. Skolnick, Ph.D., Chief Scientific Officer and a Director of the Company since May 1991, is a scientific founder of the Company. Dr. Skolnick and several colleagues were the first to conceive of using restriction fragment length polymorphism technology as genetic markers, a breakthrough that underpins the Human Genome Project. He received his Ph.D. in Genetics from Stanford University in 1975 and a B.A. degree in Economics from the University of California at Berkeley in 1968.

	Linda S. Wilson, Ph.D. Director Linda S. Wilson, Ph.D., a Director of the Company since 1999, was the President of Radcliffe College from 1989 to 1999. Prior to Radcliffe, Dr. Wilson was Vice President of Research for the University of Michigan, following ten years with the University of Illinois as the Associate Vice Chancellor for Research and Associate Dean of the Graduate College. Dr. Wilson received her Doctoral degree in Chemistry from the University of Wisconsin.

	Mark C. Capone Chief Operating Officer Myriad Genetic Laboratories, Inc. Mark C. Capone, Chief Operating Officer of Myriad Genetics Laboratories, joined the company in October 2002. He was previously Senior Vice President of Sales. Prior to joining Myriad, Mr. Capone served 17 years with Eli Lilly and Company where he held positions as Product Development Manager, Manufacturing Plant Manager, and Area Sales Director. Mr. Capone received his Bachelor of Science degree in Chemical Engineering from Penn State University graduating with highest distinction, his Master of Science degree in Chemical Engineering from Massachusetts Institute of Technology, and his Master of Science in Management from Massachusetts Institute of Technology.
	Gregory C. Critchfield, M.D. President Myriad Genetic Laboratories, Inc. Gregory Critchfield, M.D., President of Myriad Genetic Laboratories, Inc., a wholly owned subsidiary, joined the Company in July 1998. Dr. Critchfield previously served as Senior Vice President, Chief Medical and Scientific Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). Dr. Critchfield received his M.D. from the University of Utah and his M.S. in Biophysical Sciences from the University of Minnesota. He is Board Certified in Clinical Pathology.
	James S. Evans Chief Financial Officer Myriad Genetics, Inc. James S. Evans, Chief Financial Officer, joined Myriad in 1995. Mr. Evans served as Myriad's Corporate Controller from 1995 until July 2005 when he was named Vice President, Finance, a position he held until November 2007 when he was named Chief Financial Officer. Mr. Evans began his career in the Audit/Attestation division of the international accounting firm of KPMG, LLP where he held several positions. He worked as the Controller for Genmark, Inc. and Shaperite Concepts, Ltd. prior to joining Myriad. Mr. Evans received a Bachelor of Science and Master of Accounting degrees from Brigham Young University in 1987 and is a Certified Public Accountant licensed in the State of Utah.

	Robert G. Harrison Chief Information Officer Myriad Genetics, Inc. Robert G. Harrison, Chief Information Officer, joined Myriad in 1996. Mr. Harrison served as Myriad's Network Administrator from 1996 to 2000. He was then named Director of Information Systems and Technology from 2000 until January 2005. He was then named Vice President of Information Systems and Technology, a position he held until January 2008 when he was named Chief Information Officer. Mr. Harrison began his career in IT working for several private companies and consulting firms where he held several positions in technical support, sales and management capacities. Mr. Harrison received a Bachelor of Science degree in Business Administration with a minor in Computer Science from the University of Utah in 1994.
	Adrian N. Hobden, Ph.D. President Myriad Pharmaceuticals, Inc. Adrian N. Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc., a wholly-owned subsidiary, joined the Company in October 1998. Dr. Hobden was previously at Glaxo Wellcome where, over a period of 17 years, he ran a number of departments within the drug discovery area. Dr. Hobden obtained a BA in 1975 from Cambridge University and a Ph.D. from Leicester University in 1978.

	William A. Hockett, III Executive Vice President of Corporate Communications Myriad Genetics, Inc. William A. Hockett, III, Executive Vice President of Corporate Communications, joined the Company in September 1993, serving as Vice President of Marketing for Myriad Genetic Laboratories prior to assuming the head communications position. Over 19 years in the medical diagnostics industry, in research, sales and marketing roles, Mr. Hockett managed a diverse range of immunological products and services. Mr. Hockett received his B.A. in Biochemistry from the University of California, Santa Cruz.

	Jerry Lanchbury, Ph.D. Executive Vice President of Research Myriad Genetics, Inc. Jerry Lanchbury, Ph.D., Executive Vice President of Research and Development joined Myriad in January 2003. Dr. Lanchbury graduated from the University of Aston, Birmingham, UK. He earned his doctorate in population genetics from the University of Newcastle upon Tyne and subsequently completed his postdoctoral fellowship at the United Medical & Dental Schools of the University of London in Human Disease Genetics. Dr. Lanchbury is a highly respected expert in immunogenetics with more than 100 reviewed research journal publications.
	Wayne Laslie Chief Operating Officer Myriad Pharmaceuticals, Inc. Wayne Laslie, Chief Operating Officer of Myriad Pharmaceuticals, joined the Company in October 2004. Mr. Laslie was previously with Otsuka America Pharmaceutical, Inc. (OAPI), where he served as Executive Vice President for Sales and Marketing in the United States. Mr. Laslie has also served as a senior sales and marketing executive with Aventis (formerly Hoechst Marion Roussel) and held several positions with Pfizer, including Product Manager. Mr. Laslie received his Bachelor of Science degree in Biology from Georgia State University and earned his Master of Science in Microbiology from the University of Georgia.

	Richard Marsh Executive Vice President, General Counsel and Secretary Myriad Genetics, Inc. Richard Marsh, Executive Vice President, General Counsel and Secretary joined Myriad in November 2002. Prior to joining Myriad, Mr. Marsh served in various positions at Iomega Corporation including Acting General Counsel, Director of IP and Director of Commercial Legal Affairs. Richard received a Masters of Laws degree in Taxation from Georgetown University Law Center; a law degree from Thomas M. Cooley Law School, graduating magna cum laude; and an undergraduate degree in Accounting from Brigham Young University; and is a Certified Public Accountant.